Max Jan
Overview
Explore the profile of Max Jan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
2436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson R, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1859-1877.
PMID: 38393682
Purpose: Targeting solid tumors with chimeric antigen receptor (CAR) T cells remains challenging due to heterogenous target antigen expression, antigen escape, and the immunosuppressive tumor microenvironment (TME). Pancreatic cancer is...
2.
Kembuan G, Kim J, Maus M, Jan M
Trends Cancer
. 2024 Feb;
10(4):312-331.
PMID: 38355356
Chimeric antigen receptor (CAR) T cell therapy is a medical breakthrough in the treatment of B cell malignancies. There is intensive focus on developing solid tumor-targeted CAR-T cell therapies. Although...
3.
Kann M, Schneider E, Almazan A, Lane I, Bouffard A, Supper V, et al.
Leukemia
. 2023 Dec;
38(3):590-600.
PMID: 38123696
CAR-T cell therapy has emerged as a breakthrough therapy for the treatment of relapsed and refractory hematologic malignancies. However, insufficient CAR-T cell expansion and persistence is a leading cause of...
4.
Nguyen T, Sreekanth V, Deb A, Kokkonda P, Tiwari P, Donovan K, et al.
Nat Chem
. 2023 Dec;
16(2):218-228.
PMID: 38110475
Proteolysis-targeting chimeras (PROTACs) are molecules that induce proximity between target proteins and E3 ligases triggering target protein degradation. Pomalidomide, a widely used E3 ligase recruiter in PROTACs, can independently degrade...
5.
Lane I, Kembuan G, Carreiro J, Kann M, Lin W, Bouffard A, et al.
Cell Chem Biol
. 2023 Nov;
31(2):338-348.e5.
PMID: 37989314
Chimeric antigen receptor (CAR) T cell therapies are medical breakthroughs in cancer treatment. However, treatment failure is often caused by CAR T cell dysfunction. Additional approaches are needed to overcome...
6.
Bouzid H, Belk J, Jan M, Qi Y, Sarnowski C, Wirth S, et al.
Nat Med
. 2023 Jun;
29(7):1662-1670.
PMID: 37322115
Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we...
7.
Sreekanth V, Jan M, Zhao K, Lim D, Davis J, McConkey M, et al.
bioRxiv
. 2023 Mar;
PMID: 36945568
Cas9 is a programmable nuclease that has furnished transformative technologies, including base editors and transcription modulators (e.g., CRISPRi/a), but several applications of these technologies, including therapeutics, mandatorily require precision control...
8.
Haradhvala N, Leick M, Maurer K, Gohil S, Larson R, Yao N, et al.
Nat Med
. 2022 Sep;
28(9):1848-1859.
PMID: 36097221
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment;...
9.
Gigoux M, Holmstrom M, Zappasodi R, Park J, Pourpe S, Bozkus C, et al.
Sci Transl Med
. 2022 Jun;
14(649):eaba4380.
PMID: 35704596
The majority of JAK2-negative myeloproliferative neoplasms (MPNs) have disease-initiating frameshift mutations in calreticulin (), resulting in a common carboxyl-terminal mutant fragment (CALR), representing an attractive source of neoantigens for cancer...
10.
Lane I, Jan M
Trends Pharmacol Sci
. 2022 May;
43(10):804-805.
PMID: 35491262
Tumor antigen escape and T cell dysfunction limit the effectiveness of chimeric antigen receptor (CAR) T cell therapies. To overcome these challenges, Gardner et al. engineered synthetic enzyme-armed killer (SEAKER)...